ACTOVEGIN 40mg - Extract of Calf Blood

ACTOVEGIN® activates tissue metabolism, improves trophism and stimulates the regeneration process.
It is an antihypoxant that has three types of effects: metabolic, neuroprotective and microcirculatory. Actovegin® increases the absorption and utilization of oxygen. Inositol phospho-oligosaccharides, a part of the preparation, have a positive effect on the transport and utilization of glucose, that leads to an improvement in the energy metabolism of cells and a decrease in the formation of lactate under conditions of ischemia.

Several ways of implementing the neuroprotective mechanism of drug action are considered. Actovegin® prevents the development of apoptosis induced by beta-amyloid (Aβ25-35).
Actovegin® modulates the activity of nuclear factor kappa B (NF-kB), that plays an important role in the regulation of apoptosis and inflammation in the central and peripheral nervous system.
Another mechanism of action is associated with the nuclear enzyme poly (ADP-ribose) -polymerase (PARP). PARP plays an important role in detecting and repairing damage to single-stranded DNA; however, excessive activation of the enzyme can trigger cell death processes in conditions such as cerebrovascular disease and diabetic polyneuropathy. Actovegin® inhibits PARP activity, that leads to functional and morphological improvement in the state of the central and peripheral nervous system.

The positive effects of Actovegin® influencing the processes of microcirculation and endothelium are an increase in the speed of capillary blood flow, a decrease in the pericapillary zone, a decrease in the myogenic tone of precapillary arterioles and capillary sphincters, a decrease in the degree of arteriovenular shunting blood flow with predominant blood circulation in the capillary syntalis function of the endothelial nitrogen, affecting the microvasculature. In the course of various studies it was found that the effect of Actovegin® occurs no later than 30 minutes after its administration. The maximum effect is observed 3 hours after parenteral administration and 2-6 hours after oral administration.

Usage:

Ingredients:

Actovegin® concentrate (in terms of dry deproteinized hemoderivative of calf blood)
1 ml = 40 mg
1 amp = 400 mg

Dosage:

The drug is used intravenously, intravenously (including as an infusion) and intramuscularly.

Depending on the severity of the clinical picture, first, 10-20 ml of the drug should be administered intravenously or intravenously daily;
then - 5 ml intravenously or intramuscularly slowly, daily or several times a week.

For infusion, from 10 to 50 ml of the drug should be added to 200-300 ml of the stock solution (isotonic sodium chloride solution or 5% glucose solution). The infusion rate is about 2 ml / min.

For intramuscular injections, no more than 5 ml of the drug is used, that should be injected slowly, since the solution is hypertonic.

In the acute period of ischemic stroke (starting from 5-7 days) - 2000 mg / day intravenous drip up to 20 infusions with the transition to taking tablets of 2 tablets.
3 times / day (1200 mg / day). The total duration of treatment is 6 months.

With dementia - 2000 mg / day IV drip. The duration of treatment is up to 4 weeks.

In case of violations of peripheral circulation and their consequences - 800-2000 mg / day intravenously or intravenously drip. The duration of treatment is up to 4 weeks.

With diabetic polyneuropathy - 2000 mg / day intravenous drip 20 infusions with the transition to taking tablets of 3 tablets. 3 times / day (1800 mg / day). The duration of treatment is from 4 to 5 months.

Instructions for using breakpoint ampoules:
Place the tip of the ampoule point up.
Gently tapping with your finger and shaking the ampoule, let the solution flow down from the tip of the ampoule.
Holding the ampoule with the tip up in one hand, break off the tip of the ampoule with the other hand along the break point.

Form release:

Solution for injection 40 mg/1 ml.
Amp. 10 ml 5 Pcs.

Guaranteed authenticity and quality:

100% Original from  ТАКЕДА ФАРМАСЬЮТИКАЛС (Russian Federation)

Development and production:

ТАКЕДА ФАРМАСЬЮТИКАЛС (Russian Federation)